Handelsavisen
prelaunch
Companies ›Healthcare ›IRON.O
IR
IRON.O — NASDAQ Biotechnology

Disc Medicine Inc

$76,31
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-28,7 %
Net margin
—
Debt / equity
0,04
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$74,61
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

Disc Medicine Inc operates as a biotechnology company within the Health Care sector, focusing on drug discovery and development activities.

Business. Disc Medicine Inc is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and trades on the NASDAQ under the ticker symbol IRON.O. Specific details regarding operating segments and geographic revenue mix are not available.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Jennison Associates LLC
largest disclosed fund holder
Profitability→
-28,7 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning IRON.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to IRON.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Disc Medicine Inc is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and trades on the NASDAQ under the ticker symbol IRON.O. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED

    Disc Medicine Inc maintains a conservative capital structure with total liabilities of $67.1 million against total equity of $740 million, resulting in a debt-to-equity ratio of 0.04. The balance sheet includes $91.1 million in cash and equivalents and $29.2 million in long-term debt. The company reports low liquidity risk and low dilution risk, with no immediate filing-based flags detected for liquidity or dilution pressures.

    Profitability metrics reflect the pre-commercial stage of the business, with a return on equity of -28.7% and a return on assets of -26.3%. The company recorded an operating income of -$236.0 million and a net income of -$212.2 million for the latest period. These negative returns are consistent with the high burn rate typical of early-stage biotechnology firms investing in research and development prior to revenue generation.

    Segment and geographic revenue data are not provided in the available input, preventing an analysis of revenue concentration or regional exposure. The company's financial profile is dominated by operating losses rather than diversified revenue streams.

    Growth trajectory analysis is limited by the absence of historical period data in the input. The current financial snapshot shows a significant operating cash flow outflow of -$180.4 million, indicating substantial capital consumption. Capital expenditure is minimal at $0.9 million, suggesting that cash burn is primarily driven by operating expenses rather than asset acquisition.

    Risk assessment indicates low liquidity and dilution risks. The key flags section notes no immediate filing-based liquidity or dilution flags. The company's primary risk appears to be operational, centered on the ability to generate positive cash flow from operations given the current negative operating income and cash flow from operations.

    Recent news event observations indicate system-level reconciler activities for the ticker IRON.O, with no specific corporate actions, filings, or transcript events disclosed in the input data. The absence of specific news events limits the ability to assess recent market sentiment or corporate developments.

    Key takeaways
    • The company maintains a strong balance sheet with $91.1 million in cash and minimal long-term debt of $29.2 million.
    • Operating losses of $236.0 million and negative operating cash flow of $180.4 million highlight the pre-revenue nature of the business.
    • Low debt-to-equity ratio of 0.04 suggests limited financial leverage and low solvency risk.
    • No segment or geographic revenue data is available to assess diversification or concentration risks.
    • Risk assessment flags are clean, with low liquidity and dilution risks noted.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $76,31
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $739.8M
    Net cashⓘ
    $62.0M
    Current ratioⓘ
    —
    Debt / equityⓘ
    0.0
    ROAⓘ
    -26.3%
    ROEⓘ
    -28.7%
    Cash conversionⓘ
    85.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution13 analysts
    Strong buy5
    Buy8
    Hold0
    Sell0
    Strong sell0
    12-month price target$101,00 · Median $100,00
    Low $79,00High $128,00
    Operating income · consensus-299,5M USD
    EPS surprise
    +15,3 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$79,00
    Mean$101,00
    Median$100,00
    High$128,00
    Spot$76,31
    +32.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-28,7 %Above median
    D/E0,04Below median
    Cash Conv0,85Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 38 736 sh11 exercises · 11 grants12 insiders
    • Quisel John DDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockDisposed 7 416 @ $13,50exercise · 2026-07-13
    • Quisel John DDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockDisposed 25 584 @ $9,86exercise · 2026-07-13
    • Yu Jonathan Yen-WenChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 100 @ $13,50exercise · 2026-07-07
    • Khara RahulChief Legal Officer · Stock Option (Right to Buy) → Common StockDisposed 1 649 @ $14,69exercise · 2026-06-29
    • Khara RahulChief Legal Officer · Stock Option (Right to Buy) → Common StockDisposed 851 @ $14,69exercise · 2026-06-26
    • Yu Jonathan Yen-WenChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 300 @ $13,50exercise · 2026-06-26
    • Yu Jonathan Yen-WenChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 9 700 @ $13,50exercise · 2026-06-22
    • GEMAYEL GEORGESDirector · Stock Option (Right to Buy) → Common StockAcquired 6 212 @ $70,79grant · 2026-06-18
    • Khara RahulChief Legal Officer · Stock Option (Right to Buy) → Common StockDisposed 7 500 @ $14,69exercise · 2026-06-18
    • Quisel John DDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockDisposed 34 000 @ $9,86exercise · 2026-06-18
    • White William RichardDirector · Stock Option (Right to Buy) → Common StockAcquired 6 212 @ $70,79grant · 2026-06-18
    • Ratcliffe LiamDirector · Stock Option (Right to Buy) → Common StockAcquired 6 212 @ $70,79grant · 2026-06-18
    • Nicholson Donald WilliamDirector · Stock Option (Right to Buy) → Common StockAcquired 6 212 @ $70,79grant · 2026-06-18
    • Chin MarkDirector · Stock Option (Right to Buy) → Common StockAcquired 6 212 @ $70,79grant · 2026-06-18
    • Bitterman KevinDirector · Stock Option (Right to Buy) → Common StockAcquired 6 212 @ $70,79grant · 2026-06-18
    • AHMED NADIMDirector · Stock Option (Right to Buy) → Common StockAcquired 5 176 @ $70,79grant · 2026-06-18
    • Yu Jonathan Yen-WenChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 13 351 @ $9,86exercise · 2026-06-16
    • Yu Jonathan Yen-WenChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 5 261 @ $9,86exercise · 2026-06-16
    • Yu Jonathan Yen-WenChief Operating Officer · Stock Option (Right to Buy) → Common StockAcquired 25 500 @ $74,75grant · 2026-02-10
    • Khara RahulChief Legal Officer · Stock Option (Right to Buy) → Common StockAcquired 25 500 @ $74,75grant · 2026-02-10
    • Stephenson PamelaChief Commercial Officer · Stock Option (Right to Buy) → Common StockAcquired 25 500 @ $74,75grant · 2026-02-10
    • Savage William JacobChief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 25 500 @ $74,75grant · 2026-02-10

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Return On Assets
      net_income / total_assets
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    Source documents
    • Disc Medicine, Inc. Market data — financials · 2026-07-28
    • reconciler_enqueue (reconciler) on IRON.O · 2026-07-28

    Ownership & reference

    Top holders

    • Jennison Associates LLCInvestment Managers · as of 2026-03-310,03 %$39M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,02 %$111M
    • FMR LLCInstitutional Investor · as of 2026-03-310,02 %$357M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,01 %$0M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,01 %$41M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,01 %$25M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$109M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$48M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$16M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$13M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$16M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$140M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$65M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$6M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$2M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$3M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$3M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$3M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$2M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$1M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$6M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$2M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

    Leadership

    • Don W. NicholsonExecutive Chairman of the Board
    • John D. QuiselPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 31 sellsnet -$11,4M6 insiders · last 365d
    • Quisel John DDirector, Chief Executive Officer · Common StockOther 7 416 @ $13,50$100K · 2026-07-13
    • Quisel John DDirector, Chief Executive Officer · Common StockSold 6 400 @ $76,05$487K · 2026-07-13
    • Quisel John DDirector, Chief Executive Officer · Common StockOther 25 584 @ $9,86$252K · 2026-07-13
    • Quisel John DDirector, Chief Executive Officer · Common StockSold 9 704 @ $74,27$721K · 2026-07-13
    • Quisel John DDirector, Chief Executive Officer · Common StockSold 16 896 @ $74,95$1,3M · 2026-07-13
    • Yu Jonathan Yen-WenChief Operating Officer · Common StockOther 100 @ $13,50$1K · 2026-07-07
    • Yu Jonathan Yen-WenChief Operating Officer · Common StockSold 100 @ $82,50$8K · 2026-07-07
    • Khara RahulChief Legal Officer · Common StockOther 1 649 @ $14,69$24K · 2026-06-29
    • Khara RahulChief Legal Officer · Common StockSold 1 649 @ $75,00$124K · 2026-06-29
    • Yu Jonathan Yen-WenChief Operating Officer · Common StockOther 300 @ $13,50$4K · 2026-06-26
    • Yu Jonathan Yen-WenChief Operating Officer · Common StockSold 300 @ $72,50$22K · 2026-06-26
    • Khara RahulChief Legal Officer · Common StockSold 851 @ $75,00$64K · 2026-06-26
    • Khara RahulChief Legal Officer · Common StockOther 851 @ $14,69$13K · 2026-06-26
    • Yu Jonathan Yen-WenChief Operating Officer · Common StockOther 9 700 @ $13,50$131K · 2026-06-22
    • Yu Jonathan Yen-WenChief Operating Officer · Common StockSold 9 700 @ $72,66$705K · 2026-06-22
    • Khara RahulChief Legal Officer · Common StockSold 1 600 @ $70,73$113K · 2026-06-18
    • Khara RahulChief Legal Officer · Common StockOther 7 500 @ $14,69$110K · 2026-06-18
    • Khara RahulChief Legal Officer · Common StockSold 5 400 @ $69,94$378K · 2026-06-18
    • Khara RahulChief Legal Officer · Common StockSold 500 @ $71,62$36K · 2026-06-18
    • Quisel John DDirector, Chief Executive Officer · Common StockOther 34 000 @ $9,86$335K · 2026-06-18
    • Quisel John DDirector, Chief Executive Officer · Common StockSold 22 927 @ $69,92$1,6M · 2026-06-18
    • Quisel John DDirector, Chief Executive Officer · Common StockSold 9 522 @ $70,70$673K · 2026-06-18
    • Quisel John DDirector, Chief Executive Officer · Common StockSold 1 551 @ $71,61$111K · 2026-06-18
    • Yu Jonathan Yen-WenChief Operating Officer · Common StockSold 11 651 @ $68,76$801K · 2026-06-16
    • Yu Jonathan Yen-WenChief Operating Officer · Common StockOther 13 351 @ $9,86$132K · 2026-06-16

    Short positioning

    7.3Mshares short+14.6% vs prior
    10.79days to cover
    49.4%short of daily vol
    257.0Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    IRON.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Long-term debt (annual): USD 29.16MUnknown
    • Shares outstanding (annual): 37.89MUnknown
    • Cash & equivalents (annual): USD 91.14MUnknown
    • Shareholders' equity (annual): USD 739.83MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -6Unknown
    • Current liabilities (annual): USD 36.64MUnknown
    • Total liabilities (annual): USD 67.05MUnknown
    • Current assets (annual): USD 803.9MUnknown
    • Total assets (annual): USD 806.88MUnknown
    • Capex (annual): USD 933KUnknown
    • Operating cash flow (annual): USD -180.39MUnknown
    • R&D expense (annual): USD 170.64MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -6Unknown
    • Pre-tax income (annual): USD -211.82MUnknown
    • Net income (annual): USD -212.18MUnknown
    • Operating income (annual): USD -236.02MUnknown
    • Total operating expenses (annual): USD 236.02MUnknown
    • Pre-tax income (annual): USD -109MUnknown
    • Total liabilities (annual): USD 53.19MUnknown
    • Current assets (annual): USD 493.62MUnknown
    • Shares outstanding (annual): 29.87MUnknown
    • Capex (annual): USD 505KUnknown
    • Current liabilities (annual): USD 23.32MUnknown
    • Operating cash flow (annual): USD -93.93MUnknown
    Showing 24 of 34 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-13INSIDERQuisel John D transacted 7.4k sh — Director, Chief Executive Officer ~$100k
    2026-07-13INSIDERQuisel John D sold 6.4k sh — Director, Chief Executive Officer ~$487k
    2026-07-13INSIDERQuisel John D transacted 25.6k sh — Director, Chief Executive Officer ~$252k
    2026-07-13INSIDERQuisel John D sold 9.7k sh — Director, Chief Executive Officer ~$721k
    2026-07-13INSIDERQuisel John D sold 16.9k sh — Director, Chief Executive Officer ~$1.27M
    2026-07-13INSIDERQuisel John D disposed of 25.6k sh Stock Option (Right to Buy) — Director, Chief Executive Officer
    2026-07-13INSIDERQuisel John D disposed of 7.4k sh Stock Option (Right to Buy) — Director, Chief Executive Officer
    2026-07-07INSIDERYu Jonathan Yen-Wen transacted 100 sh — Chief Operating Officer ~$1k
    2026-07-07INSIDERYu Jonathan Yen-Wen sold 100 sh — Chief Operating Officer ~$8k
    2026-07-07INSIDERYu Jonathan Yen-Wen disposed of 100 sh Stock Option (Right to Buy) — Chief Operating Officer
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
    2026-06-29INSIDERKhara Rahul transacted 1.6k sh — Chief Legal Officer ~$24k
    2026-06-29INSIDERKhara Rahul sold 1.6k sh — Chief Legal Officer ~$124k
    2026-06-29INSIDERKhara Rahul disposed of 1.6k sh Stock Option (Right to Buy) — Chief Legal Officer
    2026-06-26INSIDERYu Jonathan Yen-Wen transacted 300 sh — Chief Operating Officer ~$4k
    2026-06-26INSIDERYu Jonathan Yen-Wen sold 300 sh — Chief Operating Officer ~$22k
    2026-06-26INSIDERKhara Rahul sold 851 sh — Chief Legal Officer ~$64k
    2026-06-26INSIDERKhara Rahul transacted 851 sh — Chief Legal Officer ~$13k
    2026-06-26INSIDERKhara Rahul disposed of 851 sh Stock Option (Right to Buy) — Chief Legal Officer
    2026-06-26INSIDERYu Jonathan Yen-Wen disposed of 300 sh Stock Option (Right to Buy) — Chief Operating Officer
    2026-06-22 00:00 UTCINSIDER26 insider transactions — 2026-06 · net sell $4.1M 12 derivative
    2026-06-22 00:00 UTCINSIDER26 insider transactions — 2026-06 · net sell $4.1M 12 derivative
    2026-06-22INSIDERYu Jonathan Yen-Wen transacted 9.7k sh — Chief Operating Officer ~$131k
    2026-06-22INSIDERYu Jonathan Yen-Wen sold 9.7k sh — Chief Operating Officer ~$705k
    2026-06-22INSIDERYu Jonathan Yen-Wen disposed of 9.7k sh Stock Option (Right to Buy) — Chief Operating Officer
    2026-06-18INSIDERKhara Rahul sold 1.6k sh — Chief Legal Officer ~$113k
    2026-06-18INSIDERKhara Rahul transacted 7.5k sh — Chief Legal Officer ~$110k
    2026-06-18INSIDERKhara Rahul sold 5.4k sh — Chief Legal Officer ~$378k
    2026-06-18INSIDERKhara Rahul sold 500 sh — Chief Legal Officer ~$36k
    2026-06-18INSIDERQuisel John D transacted 34.0k sh — Director, Chief Executive Officer ~$335k
    2026-06-18INSIDERQuisel John D sold 22.9k sh — Director, Chief Executive Officer ~$1.60M
    2026-06-18INSIDERQuisel John D sold 9.5k sh — Director, Chief Executive Officer ~$673k
    2026-06-18INSIDERQuisel John D sold 1.6k sh — Director, Chief Executive Officer ~$111k
    2026-06-18INSIDERBitterman Kevin acquired 6.2k sh Stock Option (Right to Buy) — Director
    2026-06-18INSIDERRatcliffe Liam acquired 6.2k sh Stock Option (Right to Buy) — Director
    2026-06-18INSIDERQuisel John D disposed of 34.0k sh Stock Option (Right to Buy) — Director, Chief Executive Officer
    2026-06-18INSIDERWhite William Richard acquired 6.2k sh Stock Option (Right to Buy) — Director
    2026-06-18INSIDERKhara Rahul disposed of 7.5k sh Stock Option (Right to Buy) — Chief Legal Officer
    2026-06-18INSIDERAHMED NADIM acquired 5.2k sh Stock Option (Right to Buy) — Director
    Showing the 40 most recent of 62 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage